The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 08, 2019

Filed:

Feb. 19, 2015
Applicant:

Wayne State University, Detroit, MI (US);

Inventors:

Wei-Zen Wei, Grosse Pointe Farms, MI (US);

Heather Gibson, Madison Heights, MI (US);

Richard Jones, Fayetteville, NY (US);

Joyce Reyes, Rochester Hills, MI (US);

Assignee:

Wayne State University, Detroit, MI (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/39 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/39 (2013.01); C07K 14/71 (2013.01); C07K 16/2863 (2013.01); C07K 16/3015 (2013.01); C07K 16/32 (2013.01); G01N 33/574 (2013.01); A61K 2039/53 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); G01N 2800/52 (2013.01);
Abstract

Antigenic polypeptides of the growth factor receptor HER2, for breaking the tolerance of a host against self HER2. The antigenic polypeptides include HER2 polypeptides with single amino acid substitutions of lysine for glutamine, arginine for glutamine, or aspartic acid for asparagine. Gene expression constructs, vaccine compositions, and immunization methods including the substituted HER2 polypeptides. Methods for immunizing mammalian subjects with heterologous unsubstituted HER2 antigenic polypeptides, including polypeptides of feline and bear HER2. A diagnostic method of determining whether a mammalian subject is sufficiently immunocompetent to respond to immunotherapies directed at breaking tolerance to self HER2.


Find Patent Forward Citations

Loading…